A U.S. federal judge on Monday denied Novo Nordisk’s motion for a preliminary injunction to block an Eli Lilly advertising campaign that compared the companies’ competing obesity drugs Wegovy and Zepbound, ruling that Novo failed to prove its false-advertising case at this stage. The decision by U.S. District Judge Zahid Quraishi means Lilly’s commercials — which lean on a head-to-head trial in which Zepbound bested the original Wegovy — can keep running while the underlying litigation continues. For the GLP-1 peptide sector, the ruling is less a verdict on marketing truth than a marker of how fiercely the two peptide-drug giants are now competing for a market analysts expect to exceed $100 billion by 2030.
What happened: injunction denied in Novo v. Lilly ad dispute
Novo sued Lilly in July 2026, alleging that Lilly’s promotions emphasizing the head-to-head trial amounted to deceptive advertising. According to court documents cited in the ruling, Novo argued the advertisements used outdated studies to compare higher doses of Lilly’s medicines with lower doses of Novo’s products, that the campaign caused “irreparable harm,” and that it failed to account for a more recently approved, higher-dose form of Wegovy.
The Monday ruling addressed only the preliminary injunction motion, not the merits of the case. In a two-day hearing in August 2026, the court heard testimony from Lilly U.S. finance chief Mark Stempel, who said Wegovy prescriptions remained stable during the April–July period the ads ran, and from Novo U.S. vice president for obesity Derrick Gastineau, who, according to Quraishi’s ruling, “had not attempted to determine” any harm.
Quraishi concluded that Novo failed to prove its case because Wegovy prescription volume did not fall when the commercials aired and because the ads acknowledged the existence of the higher-dose product. The judge also chastised Novo over separate Ozempic advertising that claimed head-to-head superiority over Lilly’s Trulicity without revealing the availability of a higher-dose version — a notable symmetry in a ruling that turns on disclosure of dose comparisons.
Key numbers behind the ruling
The ruling rests on a small set of measurable claims rather than on the science of the drugs themselves. The most consequential is the prescription-volume metric: Lilly’s witness testified that Wegovy prescriptions held steady across the April–July window during which the challenged ads aired, and the court treated that stability as undercutting Novo’s harm argument at the preliminary stage.
| Item | Figure / detail | Source |
|---|---|---|
| Ad run period examined | April–July | Testimony cited in Quraishi ruling |
| Wegovy prescription trend during ads | Remained stable (no decline shown) | Mark Stempel, Lilly U.S. finance chief |
| Injunction hearing length | Two days, August 2026 | Court record |
| Novo lawsuit filed | July 2026 | Court filing |
| Obesity market opportunity | Expected to exceed $100 billion by 2030 | Wall Street analyst estimate, per BioPharma Dive |
Two other figures frame the commercial backdrop. Tirzepatide, which Lilly sells as Zepbound for obesity and Mounjaro for diabetes, has become the industry’s best-selling product, and Lilly’s revenue growth and pipeline have helped it become biopharma’s first-ever trillion-dollar company. Novo, by contrast, held an early lead in the obesity market but has seen its value sputter as Lilly gained momentum.
Why it matters for peptide therapy and the GLP-1 supply chain
Wegovy (semaglutide) and Zepbound (tirzepatide) are peptide-based medicines, and their commercial contest shapes far more than advertising budgets. Both are GLP-1–class injectables whose demand has repeatedly strained manufacturing capacity, driven interest in fill-finish capacity for vials and cartridges, and pushed compounding pharmacies and telehealth operators into the gray zone between approved products and compounded alternatives.
For clinics, telemedicine platforms and medical spas that prescribe or dispense GLP-1 therapies, the ruling changes little about clinical practice but reinforces a compliance lesson: comparative marketing claims are legally fragile when they rest on dose mismatches or outdated trials. The court noted that Lilly altered the language in newer Zepbound ads following a cease-and-desist letter, with the updated ads noting that high-dose Wegovy exists and was not tested against Zepbound. That revision, the ruling suggests, helped neutralize Novo’s disclosure argument.
Industry observers note that the decision may signal a broader normalization of comparative advertising in the obesity category, provided claims are current and disclose dose differences. It does not establish that any particular advertising claim is true; Novo’s spokesperson said the ruling “does not constitute a final resolution of the merits” and did not “decide the question of whether Lilly’s advertising is false and misleading.”
Supply-side readers should separate the marketing dispute from the manufacturing reality. Semaglutide acts on the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors; their approved products, indications, dosing and labeling differ, and decisions about which to use belong with prescribers working from current labeling. On the production side, a peptide API is only the active ingredient — a finished drug product adds formulation, container closure, manufacturing controls, labeling and release requirements, and API quality alone does not establish finished-product quality or regulatory approval. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
Research and market context: a peptide duopoly under pressure
The litigation is one episode in what the source describes as one of the most intense commercial battles in pharmaceutical history. Lilly followed the launch of Novo’s Wegovy pill with an oral alternative of its own, extending the contest from injectables into oral peptide formulations — a format that raises distinct questions about bioavailability, dosing and manufacturing scale.
For research-peptide businesses and laboratories, the case is a reminder of category boundaries. Approved GLP-1 medicines, compounded drugs and research-use-only peptides occupy different regulatory spaces; a research-use designation does not establish sterility, safety or authorization for human administration, and a certificate of analysis does not by itself establish clinical safety. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
Clinics sourcing GLP-1 or other peptide products face a practical documentation burden that this ruling indirectly highlights: batch-specific certificates of analysis, identity and purity testing by HPLC and LC-MS, impurity characterization, traceability and clear labeling of regulatory status. Suppliers that cannot demonstrate those controls are a quality risk regardless of how the commercial battle between Novo and Lilly unfolds.
What comes next
The preliminary injunction has been denied, but the underlying case has not been decided. Novo has signaled it views the ruling as procedural rather than substantive, leaving open the possibility of further litigation on the merits. Readers should watch three things: whether Novo pursues the case beyond the injunction stage; whether Lilly’s revised ad language holds up under continued scrutiny; and whether comparative advertising in the obesity category becomes more explicit about dose and trial design as a result.
For the peptide supply chain, the more consequential variables remain capacity, quality documentation and regulatory clarity — not courtroom outcomes. Demand forecasts above $100 billion by 2030 imply continued pressure on API sourcing, fill-finish capacity for vials and dual-chamber cartridges, and cold-chain logistics. None of those constraints is resolved by a ruling on advertising, and the available evidence does not yet establish how the litigation will affect either company’s commercial trajectory.
Comments